Business
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual
About this update from Anika Therapeutics Inc.
[{"type":"image","alt":"TELA Bio, Inc.","displaySize":"","headline":null,"caption":"TELA Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ag5lqWNf2KitaJd7ewadgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMw--/https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7","width":300,"height":81}},"lazy":false},{"type":"text","content":"MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.","length":342,"tagName":"p"},{"type":"text","content":"In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy, venture capital, and corporate turnarounds. This refreshment reflects the Board’s strong commitment to positioning TELA Bio for long-term success.","length":500,"tagName":"p"},{"type":"text","content":"Departing Directors (effective at the conclusion of the 2026 Annual Meeting):","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Doug Evans, Chairman of the Board","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"Kurt Azarbarzin","length":15,"tagName":"p"}]},{"val":[{"type":"text","content":"Vince Burgess","length":13,"tagName":"p"}]},{"val":[{"type":"text","content":"Federica O’Brien","length":16,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":77,"olType":false},{"type":"text","content":"New Directors (effective immediately after the conclusion of the 2026 Annual Meeting):","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Joseph Capper will be nominated for election as a Class I director at the 2026 Annual Meeting and is expected to serve as Chair of the Board upon election","length":154,"tagNam...